PROK
ProKidney Corp. Class A · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website rokidney.com
- Employees(FY) 87
- ISIN KYG7S53R1049
Performance
+26.04%
1W
+37.42%
1M
-11.25%
3M
-38.79%
6M
+19.66%
YTD
+40.13%
1Y
Profile
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture that is in Phase I for REACT in patients with Congenital Anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Technical Analysis of PROK 2024-12-02
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2024-11-25 18:30
- 2024-11-11 18:30
- 2024-11-04 18:30
- 2024-10-22 07:02
- 2024-10-13 19:30
- 2024-10-08 19:30
- 2024-09-04 01:33
- 2024-09-02 19:30
- 2024-08-26 19:30
- 2024-08-08 19:00
- 2024-06-26 17:52
PROK Stock Earnings: ProKidney Reported Results for Q4 2023(Investorplace)
- 2024-06-26 02:10
- 2024-06-16 19:00
- 2024-06-11 09:35
- 2024-06-10 19:40
- 2024-06-10 04:15
- 2024-06-09 19:32
- 2024-06-09 18:30
- 2024-05-28 19:00
- 2024-05-20 19:00
- 2024-05-10 03:43
ProKidney Corp Reports First Quarter 2024 Financial Results(Yahoo Finance)
- 2024-05-10 01:54
PROK Stock Earnings: ProKidney Beats EPS for Q1 2024(Investorplace)
- 2024-05-09 19:48
ProKidney Q1 Loss Unchanged From Year Earlier(Yahoo Finance)
- 2024-05-09 19:00
- 2024-03-24 18:05
- 2024-03-21 07:49
- 2024-02-29 03:05
- 2023-12-28 19:22
- 2023-12-12 20:55
- 2023-11-29 17:05
Page 1 of 3
previousnext
Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.